Success Metrics

Clinical Success Rate

100.0%

Based on 8 completed trials

Completion Rate

100%(8/8)

Active Trials

2(18%)

Results Posted

75%(6 trials)

Phase Distribution

Ph not_applicable

Ph phase_4

Ph phase_1

18%

Ph early_phase_1

Ph phase_2

55%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution11 total trials

Early Phase 1First-in-human

1(9.1%)

Phase 1Safety & dosage

2(18.2%)

Phase 2Efficacy & side effects

6(54.5%)

Phase 4Post-market surveillance

1(9.1%)

N/ANon-phased studies

1(9.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

8 of 8 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(8)

Other(1)

Detailed Status

Completed8

Recruiting1

Active, not recruiting1

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Early Phase 11 (9.1%)

Phase 12 (18.2%)

Phase 26 (54.5%)

Phase 41 (9.1%)

N/A1 (9.1%)

Trials by Status

recruiting19%

active_not_recruiting19%

completed873%

unknown19%

Recent Activity

2 active trials

Showing 5 of 11

active_not_recruitingphase_1

Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple Sclerosis

NCT02391961

View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials

NCT02868567Phase 1

Use of Dalfampridine in Primary Lateral Sclerosis

Active Not Recruiting

NCT06853015Phase 1

Double Dose 4-AP on Functional Recovery After Spinal Cord Injury

Recruiting

NCT05447676Early Phase 1

Effects of 4-AP on Functional SCI Recovery

Unknown

NCT02006160Phase 2

Effects of Dalfampridine on Cognition in Multiple Sclerosis

Completed

NCT02391961Phase 2

Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple Sclerosis

Completed

NCT02166346Phase 2

Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)

Completed

NCT01621113Phase 2

Combination Therapy With Dalfampridine and Locomotor Training for Chronic, Motor Incomplete Spinal Cord Injury

Completed

NCT02656160Phase 2

Effect of Dalfampridine (4-AP) on Genioglossus Muscle Activity in Healthy Adults

Completed

NCT01975324Phase 4

A New Medicine to Treat Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)

Completed

NCT01811706Not Applicable

Dalfampridine and Gait in Spinocerebellar Ataxias

Completed

NCT01444300Phase 2

Dalfampridine for Imbalance in Multiple Sclerosis

Completed

All 11 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 11